Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector

S S Yoon1, N M Carroll, E A Chiocca

  • 1Department of Surgery, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA.

Annals of Surgery
|September 22, 1998
PubMed
Summary

The herpes simplex virus type 1 (HSV 1) vector hrR3 effectively destroys colon carcinoma cells through replication. Adding ganciclovir did not enhance hrR3

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reassessing the Management of Treatment-Induced Brain Necrosis in Metastatic Patients: Advancing Surgical Alternatives to Steroid Therapy.

Neurosurgery practice·2025
Same author

Gabapentinoids confer survival benefit in human glioblastoma.

Nature communications·2025
Same author

Leveraging next generation materials for cancer neuroscience therapies in the central nervous system.

Nature reviews. Materials·2024
Same author

Haemodynamic compensation in a patient with bilateral vertebral artery.

Hong Kong medical journal = Xianggang yi xue za zhi·2024
Same author

Comparing the efficacy of different methods of faecal microbiota transplantation via oral capsule, oesophagogastroduodenoscopy, colonoscopy, or gastric tube.

The Journal of hospital infection·2022
Same author

Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.

The British journal of surgery·2021

Area of Science:

  • Oncolytic virotherapy
  • Gene therapy
  • Herpes simplex virus (HSV) vectors

Background:

  • Most cancer gene therapies utilize non-replicating viral vectors.
  • The HSV-1 vector hrR3 replicates, exhibiting inherent cytotoxicity.
  • hrR3 targets tumor cells by selectively replicating in those with high ribonucleotide reductase levels.

Purpose of the Study:

  • To evaluate the efficacy of the hrR3 HSV-1 vector in destroying colon carcinoma cells.
  • To assess the combined effect of hrR3 and the prodrug ganciclovir.
  • To explore the potential of HSV-1 vectors for treating colorectal cancer liver metastases.

Main Methods:

  • Western blot analysis to determine ribonucleotide reductase expression in colon carcinoma cell lines and human hepatocytes.

Related Experiment Videos

  • In vitro assays to measure hrR3-mediated cytotoxicity.
  • In vivo studies using HT29 colon carcinoma xenografts in nude mice, assessing tumor growth with and without ganciclovir treatment.

    • Main Results:

    • Colon carcinoma cells exhibit significantly higher ribonucleotide reductase levels than human hepatocytes.
    • hrR3 demonstrated efficient destruction of colon carcinoma cells in vitro.
    • A single intratumoral hrR3 injection significantly reduced tumor growth in vivo, with no additive benefit from ganciclovir.

    Conclusions:

    • The replication of hrR3 is cytotoxic to colon carcinoma cells, both in vitro and in vivo.
    • Ganciclovir did not enhance the anti-tumor efficacy of hrR3 in vivo.
    • Future development of more effective and selective HSV-1 vectors holds promise for cancer treatment.